Vraylar FDA Approval History
Vraylar (cariprazine) is a dopamine D3/D2 receptor partial agonist atypical antipsychotic for the:
- treatment of schizophrenia in adults
- acute treatment of manic or mixed episodes associated with bipolar I disorder in adults
- treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
Development Timeline for Vraylar
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.